Loading
A phase 2 trial of GC101 TIL in non-small-cell lung cancer and small-cell lung cancer, run by Shanghai Juncell Therapeutics, now recruiting.
A Phase II Study of GC101 in NSCLC is a phase 2 interventional study registered as NCT07560111 by Shanghai Juncell Therapeutics, with 28 participants planned, started 2026-06-01 and due to reach its primary completion in 2027-06-01. Interventions recorded: Autologous Tumor Infiltrating Lymphocytes. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shanghai Juncell Therapeutics, GC101 TIL.
Shares GC101 TIL, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/